CONCORDBIO: 18% revenue growth, strong margins, new injectables, and global expansion drive performance

About this update from Concord Biotech Ltd.

Revenue grew 18% year-over-year to ₹1,20,009 lakhs, with net profit up 21% and EBITDA margin at 42.1%. Major investments included a new injectable facility, US and renewable energy ventures, and expanded global presence. The company remains debt-free, with a proposed dividend of ₹10.70 per share.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Concord Biotech Ltd.